"Quinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
| Descriptor ID |
D015363
|
| MeSH Number(s) |
D03.633.100.810.835
|
| Concept/Terms |
Quinolones- Quinolones
- Quinolinones
- Ketoquinolines
- Oxoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Quinolones".
Below are MeSH descriptors whose meaning is more specific than "Quinolones".
This graph shows the total number of publications written about "Quinolones" by people in this website by year, and whether "Quinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 5 | 0 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 2 | 5 |
| 2012 | 4 | 0 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
-
Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series. J Cyst Fibros. 2021 05; 20(3):399-401.
-
In?Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. Cancer Invest. 2020 Jul; 38(6):349-355.
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
-
The study of CFTR modulators in the very young. Lancet Respir Med. 2019 04; 7(4):287-289.
-
Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury. Pharmacol Res. 2019 03; 141:249-263.
-
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
-
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902.
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.
-
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.